高雪氏症治療:市場預測(2022年∼2027年)

全球高雪氏症治療的市場規模，2020年為10億1,295萬2,000美金，在預測期間內預計以2.74％的年複合成長率發展，預計至2027年達到12億2,395萬5,000美元。

本報告提供全球高雪氏症治療市場調查，市場規模和預測，市場促進因素及課題，市場趨勢，治療的各類型、疾病的各類型、各終端用戶、各地區的市場分析，競爭情形，主要企業的簡介等系統性資訊。

目錄

第1章 簡介

• 市場定義
• 市場區隔

第2章 調查手法

• 調查資料
• 前提條件

第3章 摘要整理

• 調查的重點

第4章 市場動態

• 推動市場要素
• 阻礙市場要素
• 波特的五力分析
  • 供給企業談判力
  • 買主談判力
  • 替代品的威脅
  • 新加入業者的威脅
  • 競爭企業間的敵對關係
• 產業的價值鏈分析

第5章 高雪氏症治療市場:治療的各類型

• 簡介
• 酵素補充療法(ERT)
• 基材減少療法(SRT)
• 外科的治療

第6章 高雪氏症治療市場:疾病的各類型

• 簡介
• I型
• II 型
• III 型

第7章 高雪氏症治療市場:各終端用戶

• 簡介
• 醫院
• 門診病人專門診所
• 臨床研究機關

第8章 高雪氏症治療市場:各地區

• 簡介
• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 南美
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 英國
  • 德國
  • 法國
  • 其他
• 中東、非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 其他
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 泰國
  • 印尼
  • 台灣
  • 其他

第9章 競爭環境與分析

• 主要企業策略分析
• 新興企業和市場收益性
• 合併，收購，協定，及合作
• 供應商競爭力矩陣

第10章 企業簡介

• AVROBIO Inc.
• Gain Therapeutics, Inc.
• Pfizer Inc.
• Prevail Therapeutics
• Sanofi
• Evotech
• CANbridge Life Sciences Ltd.
• Lysogene
• Orphazyme
• Freeline

The Gaucher disease treatment market is projected to grow at a CAGR of 2.74% during the forecast period to reach US$1,223.955 million by 2027, from US$1012.952 million in 2020.

Gaucher disease is characterized by the build-up of glucocerebroside in cells and some organs, resulting in enlargement of the liver as well as the spleen. It is a genetic disease that shows symptoms such as fatigue, bruising, anemia, and a low blood platelet count and is caused by a hereditary deficit of the enzyme glucocerebrosidase. Despite being the most common lysosomal storage disorder, Gaucher disease is a rare ailment with an incidence of 1 in 100,000 people.

One of the key reasons driving the Gaucher disease treatment market during the forecast period is the rising prevalence of Gaucher worldwide. Factors such as increasing Gaucher disease incidences and pharmaceutical companies' increased focus on developing innovative pharmaceuticals for treating Gaucher disease are likely to contribute to the market's growth significantly. Furthermore, rising concern for the growing incidences of Gaucher disease amongst people worldwide, combined with increasing government support and funding and rising per capita healthcare expenditure by several nations worldwide, are some of the factors expected to drive the growth of the global Gaucher disease market. According to the Centers for Medicare and Medicaid Services, healthcare spending in the United States increased by 4.6 percent in 2019 to US$ 3.8 trillion, or US$ 11,582 per person, accounting for 17.7 percent of GDP. Furthermore, the federal government accounted for 29.0 percent of total health expenditures, with families coming in second (28.4 percent). State and municipal governments accounted for 16.1 percent of overall healthcare expenditures, with other private sources accounting for the remaining 7.5 percent.

The market for Gaucher treatment may be limited by the high cost of treatment for the condition. Stringent government regulations governing the use of medications and therapies for the condition, as well as the high cost of enzyme replacement therapy and a lack of therapeutic options in poorer nations, may have an impact on market growth.

Key Developments

In 2021, the National Gaucher Foundation (NGF) started the Stepping Stones sustainer donating program. The long-term goal of this strategy is to provide a consistent source of funding for patient advocacy programs and provide financial assistance to the 6,000 persons in the United States who have Gaucher disease. Lysogene announced a research partnership with the Weizmann Institute of Science in July 2020 to produce a unique AAV gene therapy strategy for neuronopathic Gaucher's disease, Parkinson's disease, and other disorders caused by the GBA1 gene abnormalities. In 2020, Centogene and Evotec expanded their drug discovery collaboration focused on the protein target glucocerebrosidase, focusing on Gaucher's Disease. Gain Therapeutics, Inc. made a significant breakthrough in November 2021 in the potential to treat neurodegenerative disorders characterized by misfolded proteins, such as Alzheimer's Disease, Gaucher's Disease, and Parkinson's Disease.

By treatment type, the Gaucher disease treatment market is segmented into Enzyme Replacement Treatment type (ERT), Substrate Reduction Treatment (SRT), and surgical procedures. The ERT segment is expected to have a dominant market position owing to the rising global use of treating Gaucher disease and improved knowledge of the use of Enzyme Replacement Treatment.

By disease type, the Gaucher disease treatment market is segmented into Type I, Type II, and Type III. Due to the increasing number of patients suffering from type I Gaucher disease worldwide, type I Gaucher disease is seen to be the market's dominant category. Type I Gaucher affects around 95 percent of the population, making it the most common type of disease, according to the National Gaucher Foundation.

By end-users, the Gaucher disease treatment market is segmented into hospitals, ambulatory surgical centers, and clinical research institutes. Preference for hospitals is expected to fuel the segment's growth due to the availability of innovative technology and many facilities available on a single site.

By geography, the Gaucher disease treatment market is segmented into five regions - North America, Europe, South America, the Middle East and Africa, and Asia Pacific regions. North America is expected to have the most significant market share in the Gaucher disease treatment market due to the increasing number of people suffering from the condition and expanding awareness of the utilization of effective treatment alternatives. The presence of prominent market players in the region, as well as their revenue-generating tactics, is also propelling the regional market forward. Because of increased awareness initiatives about Gaucher disease treatment, the European Gaucher disease treatment market is likely to remain the second-largest market.

COVID-19 Insights

The COVID-19 epidemic has resulted in various hurdles to medical care delivery, which vary based on a patient's underlying illness. Because of the pandemic, lockdown measures were implemented, prohibiting patient movement and identification, as well as severely overburdening healthcare institutions while raising concerns among patients. It will have a significant impact on the Gaucher disease treatment market. The COVID 19 outbreak would result in excessively long wait times for patients needing certain treatments.

Market Segmentation:

• By Treatment type

Enzyme Replacement Therapy (ERT)

Substrate Reduction Therapy (SRT)

Surgical Procedure

• By Disease Type

type I

type II

type III

• By End-Users

Hospitals

Ambulatory Specialty Clinics

Clinical Research Institutes

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• United Kingdom
• Germany
• France
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• South Africa
• Others

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
• Indonesia
• Taiwan
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Definition
• 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Powers of Buyers
  • 4.3.3. Threat of Substitutes
  • 4.3.4. Threat of New Entrants
  • 4.3.5. Competitive Rivalry in Industry
• 4.4. Industry Value Chain Analysis

5. GAUCHER DISEASE TREATMENT MARKET, BY TREATMENT TYPE 

• 5.1. Introduction
• 5.2. Enzyme Replacement Therapy (ERT)
• 5.3. Substrate Reduction Therapy (SRT)
• 5.4. Surgical Procedures

6. GAUCHER DISEASE TREATMENT MARKET, BY DISEASE TYPE

• 6.1. Introduction
• 6.2. Type I
• 6.3. Type II
• 6.4. Type III

7. GAUCHER DISEASE TREATMENT MARKET, BY END-USERS

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Ambulatory Specialty Clinics 
• 7.4. Clinical Research Institutes

8. GAUCHER DISEASE TREATMENT MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom 
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. South Africa
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Thailand
  • 8.6.6. Indonesia
  • 8.6.7. Taiwan
  • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisition, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES 

• 10.1. AVROBIO Inc.
• 10.2. Gain Therapeutics, Inc.
• 10.3. Pfizer Inc.
• 10.4. Prevail Therapeutics
• 10.5. Sanofi
• 10.6. Evotech
• 10.7. CANbridge Life Sciences Ltd.
• 10.8. Lysogene
• 10.9. Orphazyme
• 10.10. Freeline